Asset
Vorasidenib
Agios Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03960502 | phase1 | completed | 2019-05-16 | 2019-09-07 | Agios Pharmaceuticals, Inc. | A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881 |
| NCT04015687 | phase1 | completed | 2019-07-15 | 2019-10-09 | Agios Pharmaceuticals, Inc. | A Study to Evaluate the Effect of AG-881 on the Pharmacokinetics of a Single Dose of Lamotrigine in Healthy Adults |
FDA applications (0)
This company has no applications containing this asset.